Sharsheret stands with Israel and hopes for lasting peace as we continue to provide vital cancer education and support.



"I learned about Sharsheret through my sorority Alpha Epsilon Phi while a student at American University. Fast-forward 5 years, I was married and underwent genetic testing prior to having children. I was surprised to learn that I tested positive for a potentially dangerous mutation and even more surprised to learn that I was a *BRCA2* mutation carrier. As you can imagine, my stress and anxiety levels were through the roof. And then I called Sharsheret." Read more from Rachel.



On February 14th, thousands worldwide will unite for Sharsheret Pink Day. Together, we will raise awareness about breast cancer and ovarian cancer and help save lives through education. Click to learn more and register to bring Pink Day to your school, organization or company.

Get Involved With Pink Day Today

Contact Ellen Kleinhaus to learn more.

Pink Day is made possible with support from <u>Daiichi-Sankyo</u> and <u>Merck</u>. The Beatrice Milberg Campus Program is made possible with support from Sherry and Neil Cohen.

Sharsheret, along with our campus partners, is proud to bring important lifesaving events to campuses across the country.

In 2023

Moishe House Partnership



For the 14th year this February, Sharsheret is partnering with Moishe Houses across the globe to provide lifesaving educational programs. Contact <u>Sarah Eagle</u> to learn more about coordinating an educational program with Sharsheret and your Moishe House. <u>Read more about our partnership here</u>.

Don't Miss Upcoming Webinars

Preparing For Life After Breast Cancer

2/4 Register Here

Make Your Words Matter: Sharsheret Ambassador & Speaker Training

2/6 Register Here

Kick Off Pink Day: Mandala Therapeutic Art
Workshop

2/13 Register Here

Coping Mechanisms To Reduce Cancer-Related
Stress: For Health Care Professionals

2/21 Regiser Here

Peer Support Training

2/28 Register Here

Webinar Sponsors:

Preparing For Life After Breast Cancer is in partnership with <u>JOWMA</u>.

Mandala art webinar is made possible with support from: <u>Daiichi-Sankyo</u>, and <u>Merck</u>, and
The Beatrice Milberg Campus Program is made possible with support from Sherry and Neil Cohen.

Peer support training webinar is made possible with support from the Cooperative Agreement DP19-1906 from the
Centers for Disease Control and Prevention and <u>Genentech</u>.



Midwest Regional Director in Chicago Area

Tri-State Outreach Manager

National Outreach Associate

Summer Interns in Teaneck and Los Angeles

Board Of Directors Update

Sharsheret welcomes a new Executive Board slate: <u>Jordanna Nadritch</u>, <u>President</u>; <u>Batya Paul, Vice President</u>; <u>Daniel Silvermintz</u>, <u>Treasurer</u>; and <u>Lizzy Greif</u>, <u>Secretary</u>
Jillian Mehlman joins us as our newest board member. <u>Stacy Smollin Schwartz</u>
completes her term as President and will stay on as Immediate Past President in the
year ahead. We want to thank Kim Molstre and Jonathan Blinken, as they rotate off the
board, for their years of service. <u>Read more here</u>.







Jillian Mehlman

Sharsheret CEO Joins Global Jewry Advisory Board

Elana Silber has joined the Global Jewry advisory board. Global Jewry is a new, grassroots effort to broaden and strengthen the ties that bind the Jewish people to one another.

Learn more here.





Sharsheret is a national not-for-profit cancer support and education organization and does not provide any medical advice or perform any medical procedures. Sharsheret does not endorse or promote any specific medication, treatment, product or service, and makes no guarantees regarding the effectiveness of the product discussed herein. The information provided herein is not a substitute for professional medical advice or treatment. You should always seek the advice of your physician or other qualified health provider.

SPONSORED CONTENT

Are You ESR1 Out of 2? Get Tested. Know Your Status.

Nearly 1 out of 2 people with ER+/HER2- metastatic breast cancer will develop an ESR1 mutation as a result of exposure to hormone therapy. The ESR1 mutation can occur when cancer changes in an attempt to evade treatments. This mutation can make your mBC harder to treat, but the good news is there is a treatment for appropriate patients with ESR1-mutated advanced or metastatic breast cancer. A simple blood draw can help determine if your cancer has developed this mutation. Do you know your ESR1 status?

Talk with your doctor about if or when to test.

Learn more at https://bit.ly/knowesr1





Gain the most insight into your best treatment options through genetic testing.

A cancer diagnosis opens many questions about the right treatment decisions. Genetic testing can bring important health details to light so you and your provider can make informed, confident choices for a treatment plan tailored to you.

Learn more by visiting https://myriad.com/oncology/patients/.



CLICK HERE TO DONATE NOW

February 2024 | Sharsheret | 866 474 2774 | info@sharsheret.org | www.sharsheret.org

STAY CONNECTED











Sharsheret | 10 East 40th Street, 28th Floor, New York, NY 10016

Unsubscribe jaltman@sharsheret.org

<u>Update Profile</u> |Constant Contact Data <u>Notice</u>

Sent byinfo@sharsheret.org